CLOs on the Move

Cyteir

www.cyteir.com

 
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cyteir.com
  • 128 Spring Street Building A, Suite 510
    Lexington, MA USA 02421
  • Phone: 857.285.4140

Executives

Name Title Contact Details
Adam Veness
 General Counsel Profile

Similar Companies

Salix

Salix is committed to being the leading US specialty pharmaceutical company licensing, developing, and marketing innovative products to healthcare professionals to treat gastrointestinal disorders in patients.

Spartan Micro

RoslinCT

RoslinCT is a UK-based Cell and Gene Therapy Contract Development and Manufacturing Organisation (CDMO) that provides services for companies developing cell and gene-based therapeutic products. They offer a range of integrated services from GMP transla...

X-37

X-37 is a pharmaceutical discovery and development company

Egalet

Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.